Efficient trial designs to reduce placebo requirements.
This brief discussion summarizes possible trial design changes that could be utilized to reduce the number of subjects exposed to ineffective treatment--in this case placebo; however, these designs are fairly complex and have not been implemented sufficiently to judge their utility. Clearly, such studies are essential before embarking on these paradigms as a primary method for assessing antidepressant efficacy.
Krishnan
K R
KR
Department of Psychiatry, Duke University Medical Center, Box 3018, Durham, NC 27710, USA.
D000928:Antidepressive Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000592:standards*; D003863:Depression / Q000188:drug therapy*; D006801:Humans; D010919:Placebos / Q000627:therapeutic use*; D016896:Treatment Outcome
D000928:Antidepressive Agents; D010919:Placebos